Post‐Transplant Malignancy and Lymphoproliferative Diseases

Absalon, Michael J.; Chin, Clifford; Rotz, Seth J.; Ryan, Thomas D.

doi:10.1002/9781119633884.ch37

Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease 2023

DOI: 10.1002/9781119633884.ch37

|View full text |Cite

Post‐Transplant Malignancy and Lymphoproliferative Diseases

Michael J. Absalon,

Clifford Chin,

Seth J. Rotz

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The novel immune landscape of immune‐checkpoint blockade in EBV‐associated malignancies

Zhang,

Li,

Zheng

et al. 2024

The FASEB Journal

View full text Add to dashboard Cite

The Epstein–Barr virus (EBV) is a ubiquitous gamma‐herpesvirus and a class 1 carcinogen that is closely associated with a series of malignant lymphomas and epithelial cell carcinomas. Although these EBV‐related cancers may exhibit different features in clinical symptoms and anatomical sites, they all have a characteristic immune‐suppressed tumor immune microenvironment (TIME) that is tightly correlated with an abundance of tumor‐infiltrating lymphocytes (TILs) that primarily result from the EBV infection. Overwhelming evidence indicates that an upregulation of immune‐checkpoint molecules is a powerful strategy employed by the EBV to escape immune surveillance. While previous studies have mainly focused on the therapeutic effects of PD‐1 and CTLA‐4 blockades in treating EBV‐associated tumors, several novel inhibitory receptors (e.g., CD47, LAG‐3, TIM‐3, VISTA, and DDR1) have recently been identified as potential targets for treating EBV‐associated malignancies (EBVaMs). This review retrospectively summarizes the biological mechanisms used for immune checkpoint evasion in EBV‐associated tumors. Its purpose is to update our current knowledge concerning the underlying mechanisms by which an immune checkpoint blockade triggers host antitumor immunity against EBVaMs. Additionally, this review may help investigators to more fully understand the correlation between EBV infection and tumor development and subsequently develop novel therapeutic strategies.

show abstract

The novel immune landscape of immune‐checkpoint blockade in EBV‐associated malignancies

Zhang,

Li,

Zheng

et al. 2024

The FASEB Journal

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Post‐Transplant Malignancy and Lymphoproliferative Diseases

Cited by 1 publication

References 134 publications

The novel immune landscape of immune‐checkpoint blockade in EBV‐associated malignancies

The novel immune landscape of immune‐checkpoint blockade in EBV‐associated malignancies

Contact Info

Product

Resources

About